Improving outcome of treatment of Kala-Azar by supplementation of amphotericin B with physiologic saline and potassium chloride

American Journal of Tropical Medicine and Hygiene

Volumn 83, Issue 5, 2010, Pages 1040-1043

  Thakur, Chandeshwar P ^a   Kumar, A ^a   Mitra, Dipendra K ^b   Roy, Ambak ^b   Sinha, Arun Kumar ^c   Ranjan, Alok ^d  

^a Balaji Utthan Sansthan   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c PATNA UNIVERSITY   (India)

^d INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIPYRETIC AGENT; CREATININE; DEXAMETHASONE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; ANTIPROTOZOAL AGENT; ELECTROLYTE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEVER; HUMAN; KIDNEY DISEASE; LEISHMANIASIS; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RIGOR; SCHOOL CHILD; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; CHEMICALLY INDUCED DISORDER; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; VISCERAL LEISHMANIASIS;

NASO HEXACANTHUS;

AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; CHILLS; CREATININE; ELECTROLYTES; FEVER; HUMANS; LEISHMANIASIS, VISCERAL; POTASSIUM CHLORIDE; SODIUM CHLORIDE;

EID: 79952058096     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2010.10-0255     Document Type: Article

References (28)

1. Prata A, 1963. Treatment of kala-azar with amphotericin B. Trans R Soc Trop Med Hyg 57: 266-268.
2. Thakur CP, 1993. Diminishing effectiveness of currently used drugs in treatment of kala-azar and amphotericin B in antimony and pentamidine resistant kala-azar. Kumar S, ed. Current Trends in Leishmania Research. New Delhi, India: Council of Scientific and Industrial Research, India: 254-262.
3. Mishra M, Singh MP, Choudhury D, Singh VP, Khan AP, 1991. Amphotericin B for second line treatment of Indian kala-azar. Lancet 337: 926.
4. Lira R, Sundar S, Makharia A, Keeny R, Gam A, Saraiva E, Sack D, 1999. Evidence that the high incidence of treatment failure in kala-azar is due to the emergence of antimony resistant strains of Leshmania donovani. J Infect Dis 180: 564-567. (Pubitemid 30256350)
5. Thakur CP, Sinha SP, Sharma V, Pandey AK, Kumar M, Verma BB, 1993. Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar. Indian J Med Res 97: 170-175. (Pubitemid 23294283)
6. Thakur CP, Kumar A, Mitra G, Thakur S, Sinha PK, Das P, Bhattacharya SK, Sinha A, 2008. Impact of amphotericin B in the treatment of kala-azar on the incidence of PKDL in Bihar, India. Indian J Med Res 128: 58-64.
7. Saha S, Mondal S, Ravindran R, Bhowmick S, Modak D, Mallick S, Rahman M, Kar S, Goswami R, Guha SK, Pramanik N, Saha B, Ali N, 2007. IL-10- and TGF-β-mediated susceptibility in kalaazar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. J Immunol 179: 5592-5603.
8. Gallis HA, Drew RH, Pickard WW, 1990. Amphotericin B. 30 years of clinical experience. Rev Infect Dis 12: 308-329.
9. Bindschadler DD, Bennett JE, 1969. A pharmacological guide to the clinical use of amphotericin B. J Infect Dis 120: 427-436.
10. Khoo SH, Bond J, Denning DW, 1994. Administering amphotericin B - a practical approach. J Antimicrob Chemother 33: 203-213. (Pubitemid 24076799)
11. Thakur CP, 1995. Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration. Natl Med J India 8: 13-14.
12. Thakur CP, 1998. Sodium antimony gluconate, amphotericin, and myocardial damage. Lancet 27: 1928-1929. (Pubitemid 28297453)
13. Nuzum E, White F III, Thakur CP, Dietze R, Wages J, Grogl M, Berman J, 1995. Diagnosis of symptomatic visceral leishmaniasis by use of the polymerase chain reaction on patient blood. J Infect Dis 171: 751-754.
14. Thakur CP, Sinha GP, Pandey AK, 1996. Comparison of regimens of amphotericin B deoxycholate in kala-azar. Indian J Med Res 103: 259-263. (Pubitemid 26164495)
15. Jha TK, Giri YN, Singh TK, Jha S, 1995. Use of amphotericin in drug resistant cases of visceral leishmaniasis in North Bihar, India. Am J Trop Med Hyg 52: 336-538.
16. Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A, 1999. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg 93: 319-323. (Pubitemid 29348832)
17. Bhattacharya SK, Sinha PK, Thakur CP, Jha TK, Pandey K, Das VR, Kumar N, Lal C, Verma N, Singh VP, Ranjan A, Verma RB, Anders G, Sindermann H, Ganguly NK, 2007. Phase-4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis 196: 591-598. (Pubitemid 47206107)
18. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK, 2007. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 356: 2571-2581. (Pubitemid 46961002)
19. Fisher Exact Test, 1998. Available at: http://hedwig.mgh.harvard.edu/ sample-size/fisher/fishapp.html.
20. Medical Journal of Australia, 2002. Determining the Sample Size in a Clinical Trial. Available at: http://www.mja.com.au/public/issues/177-05-020902/ kir10425-fm.html.
21. Chulay JD, Bryceson AD, 1983. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 32: 475-479. (Pubitemid 13101435)
22. Cancer Therapy Evaluation Program, Common Toxicity Criteria. Rockville, MD: National Cancer Institute, 2002. Available at: http://ctep.cancer.gov/ reporting /index.html Accessed December 7, 2003.
23. Sundar R, Rai M, 2002. Advances in the treatment of visceral leishmaniasis. Curr Opin Infect Dis 15: 593-598.
24. Sundar S, Chatterjee M, 2006. Visceral leishmaniasis - current therapeutic modalities. Indian J Med Res 123: 345-352. (Pubitemid 43905574)
25. Bailey JE, Meyers C, Keigman RM, 1990. Pharmacokinetics; outcome of treatment and toxic effects of amphotericin B and 5 flucytosine in neonates. J Pediatr 116: 791.
26. Amphotericin B, 2009. Available at: http://www.google.co.in/search9hl= en&source=hp&q=amphotericin+B+&meta=saq=f408/26/2009.
27. Ramakant B, Kala-Azar Patients Lack Adequate Diagnosis and Drug. February 5th, 2009-8:59 pm ICT by admin. Available at: http://www.thaindian.com/ newsportal/health/kala-azar-patients-lack-adequate-diagnosis-and-drugs-10015619. html.
28. Thakur CP, 2007. A new strategy for elimination of kala-azar from rural Bihar. Indian J Med Res 126: 447-451. (Pubitemid 351663601)